PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66),销售额$2.13亿 低于预期$2.3244亿

财报速递2025-02-28
PTC Therapeutics(纳斯达克代码:PTCT)报告季度每股亏损$(0.85),低于分析师一致预期的$(0.66),差距为28.79%。与去年同期每股亏损$(0.24)相比,同比下降254.17%。公司报告季度销售额为$2.13亿美元,低于分析师一致预期的$2.3244亿美元,差距为8.36%。与去年同期的$3.0706亿美元销售额相比,同比下降30.63%。

以上内容来自Benzinga Earnings专栏,原文如下:

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.66) by 28.79 percent. This is a 254.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $213.00 million which missed the analyst consensus estimate of $232.44 million by 8.36 percent. This is a 30.63 percent decrease over sales of $307.06 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法